Participant flow

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL · Source last updated 2026-03-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Bendamustine + rituximab in participants with chronic lymphocytic leukemia (CLL) without deletion 17p \[del(17p)\]; bendamustine 90 milligrams (mg)/m\^2/day administered intravenously (IV) on the first 2 days of each cycle for 6 cycles; rituximab 375 mg/m\^2 for Cycle 1 and 500 mg/m\^2 for Cycles 2 to 6 (each cycle is 28 days)

   id

   FG000

   title

   Cohort 1: Bendamustine + Rituximab Without Del(17p)

2. description

   Zanubrutinib in participants with CLL without del(17p); 160 mg administered twice a day orally until unacceptable toxicity or disease progression

   id

   FG001

   title

   Cohort 1: Zanubrutinib Without Del(17p)

3. description

   Zanubrutinib in participants with CLL with del(17p); 160 mg administered twice a day orally until unacceptable toxicity or disease progression

   id

   FG002

   title

   Cohort 2: Zanubrutinib With Del(17p)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         202

      2. group Id

         FG001

         num Subjects

         219

      3. group Id

         FG002

         num Subjects

         102

      type

      Remained on study at time of data cut-off

   2. reasons

      1. group Id

         FG000

         num Subjects

         14

      2. group Id

         FG001

         num Subjects

         16

      3. group Id

         FG002

         num Subjects

         8

      type

      Death

   3. reasons

      1. group Id

         FG000

         num Subjects

         16

      2. group Id

         FG001

         num Subjects

         5

      3. group Id

         FG002

         num Subjects

         1

      type

      Withdrawal by Subject

   4. reasons

      1. group Id

         FG000

         num Subjects

         5

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         0

      type

      Physician Decision

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      type

      Lost to Follow-up

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         238

      2. group Id

         FG001

         num Subjects

         241

      3. group Id

         FG002

         num Subjects

         111

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         227

      2. group Id

         FG001

         num Subjects

         240

      3. group Id

         FG002

         num Subjects

         111

      type

      Treated

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         238

      2. group Id

         FG001

         num Subjects

         241

      3. group Id

         FG002

         num Subjects

         111

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Available data are presented as of the primary analysis data cut-off date of 07MAY2021; as of the data cut-off date, all cohorts were ongoing.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice